anonymous
Guest
anonymous
Guest
Sucks that associate reps will pay the price for leadership over hiring. Shame on them.
Sucks that associate reps will pay the price for leadership over hiring. Shame on them.
Anyone actually keeping count of the layoffs? Rumor has it, it’s way more that 29.
1st round?
More to come due to marketing headwinds.
GG, BG, JL jam too many reps into territories. Everyone in the field pushes back. They decide to move forward anyway. A year later they fire a bunch of these people. Put a huge wrench in these people’s lives.
Youall remember when BG said he was going to expand operations in 2022… and instead bloated the sales force while we all laughed at the misstep.
Now 29 have no jobs and many others internally.
Yet BG,JL, and GG - nothing. No consequences for terrible leadership and toddler level strategy.
MDXG heading towards twice the Market Cap of ORGO. Maybe MDXG would be a good model for rebuilding a leadership team.This is what happens when your entire business model hinges on taking advantage of medicare loopholes.
MDXG heading towards twice the Market Cap of ORGO. Maybe MDXG would be a good model for rebuilding a leadership team.
Sucks that associate reps will pay the price for leadership over hiring. Shame on them.
I'll never forget when my Senior Director told us this strategy from Brian Grow as if it was some brilliant idea. I interviewed people but refused to hire anyone because it was so obvious that this outcome was inevitable. This company is truly spiraling. You can't promote that much useless talent from within and expect a great long term outcome. A large majority of the people in the management meetings, I wouldn't even hire as reps at other companies I've worked for. It really is a pathetic group.GG November 2022:
Let me update you on the progress of each of these in Q3. First, our commercial team has grown to 365 direct representatives up 11% year-over-year, and we believe our commercial team continues to represent a key competitive advantage for Organogenesis. The strength of our sales force enables continued expansion across the country and deeper penetration as our team increases awareness of the benefits of our advanced technologies.
3 months later
GGFebruary 2023:
I have difficult news to share.
We operate in a complex market with increasingly challenging economic conditions, which we expect to continue for the foreseeable future. To ensure Organogenesis remains a market leader, we performed a rigorous operational review to improve productivity and increase efficiency to be better prepared for the future.
As a result, we made the difficult decision to reduce our workforce by approximately 7% across the company and notified impacted employees earlier today.